Abstract
Stents have been increasingly used in treating the venous anastomosis stenosis of the arteriovenous grafts (AVG). Further, stents offer significantly better patency rate compared to angioplasty. However, scarce data are available about the outcomes of the stents used in treating thigh AVG dysfunction. This study sought to assess the primary and secondary patency rates of stents used in thigh AVGs at one year. We retrospectively reviewed the medical records of all the patients who had thigh AVG that underwent stent placement between January 2005 and June 2017 at the University of Alabama at Birmingham. The primary and secondary patency rates were defined as the time between stent deployment and the first intervention and second intervention, respectively. Kaplan-Meier survival analyses were used to calculate the time-to-first and second interventions. This study included 50 patients with thigh AVG; mean age was 50.5± 15.5 year; 52% were females; 80% were black; 90% had hypertension. The main indication for stenting was thrombosis due to venous anastomosis stenosis (74%). The number (mean ± SD) of stents placed was 1.24 ± 0.8. The primary patency rate at 3 month and 1-year was 58.7% and 30.7%. In comparison, the secondary patency rate at 3 month and 1-year was 68.2% and 40.7% (p=0.04) [Fig 1]. While stenting the thigh AVGs has poor primary patency rate at one year, the secondary patency rate is significantly better during the first year after stenting. Further prospective randomized clinical trials are needed.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.